PubMed · 4609499
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
I G Morris. 1974. Immunological proteins.. https://pubmed.ncbi.nlm.nih.gov/4609499/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
BACKGROUND: Urologists are looking for a way to easily discriminate between aggressive and very slow-growing prostate tumors. A sound way to appreciate such developing activities would be to identify an appropriate cell marker in prostate explants maintained in a defined culture system. METHODS: Different biological parameters were compared in rat prostate explants cultured for 5 days in rich CMRL or basic Leibovitz's L-15 medium, unsupplemented with serum, under a mixture of either 95% air/5% CO2 or 50% N2/45% O2/5% CO2. RESULTS: DNA synthesis was somewhat similar with the two-gas combination, but was higher in explants maintained in L-15 medium than in CMRL. Hence, L-15 medium and the 95% air/5% CO2 mixture were selected. Under these defined conditions for 5 days, cells were still able to synthesize DNA and proteins while preserving their morphological integrity and maintaining alkaline and acid phosphatase activities. CONCLUSIONS: Since the present culture system works well in a controlled environment and under such minimal conditions, it appears to be a reliable and promising model that will provide basic data and allow the study of hormones and growth factors involved in prostatic tissue growth. It might eventually permit the identification of a cell marker.
BACKGROUND: The incidence and mortality of prostate cancer are increasing at alarming rates, partially due to an aging population. Early detection of prostate cancer, using clinically sensitive procedures and/or tumor markers (e.g., prostate-specific antigen [PSA]), is of prime importance. However, the choice of therapeutic interventions for prostate cancer at the time of diagnosis is largely dependent on clinical and pathologic staging and prediction of the degree of aggressiveness of the disease. Clinically applicable prognostic markers are urgently needed to assist in the selection of optimal therapy. METHODS: Literature review of the potential diagnostic and prognostic markers for human prostate cancer. RESULTS: Well-established tissue prognostic indicators, including histologic grade, margin positivity, pathologic stage, intraglandular tumor extent, and DNA ploidy, are not reviewed in this paper. Recently, a number of novel markers have been identified. In this paper, we begin with a discussion of a number of well-established as well as investigational diagnostic markers and then focus on evaluation of prognostic markers. Diagnostic markers that have prognostic value and investigational prognostic markers are also discussed. CONCLUSIONS: Currently, only PSA is utilized for early diagnosis and monitoring of prostate cancer. A number of potential prognostic markers warrant further investigation. Multimarker analysis is implicated.
Activin A, a homodimer of the betaA subunit of inhibin, is a member of the TGF-beta family. It is a multifunctional molecule regulating the growth, differentiation, and survival of a variety of cells. Treatment with activin A to an androgen-sensitive human prostatic cancer cell line LNCaP resulted in growth and morphological change and those were accompanied by up-regulation of prostatic differentiation markers prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP). In addition, the expression of androgen receptor was also enhanced by activin treatment. These results suggest that activin has significant influence on LNCaP cells.